top
Search terms
Results 1 - 10 of 15 - ordered by :
Pages: 1 2
Ehjcvp

Abstract Aims An important decision in the management of patients with atrial fibrillation is whether to adopt a rate or rhythm control strategy. Methods and results We conducted a retrospective ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Carl Hayward, Hitesh C. Patel, Ketna Patel, Carlo Di Mario, Alexander R. Lyon, Syed Y. Ahsan, Edward Rowland

Date : 01/04/2016 Item size : 222623 bytes
Ehjcvp

[...]of progress made in HFREF therapy, cumulative mortality benefit amounts to almost a three-fold decrease in death rate whether in severe or in mild-to-moderate HFREF. In chronic HEFREF, it is ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Faiez Zannad

Date : 01/01/2015 Item size : 180641 bytes
Ehjcvp

Recent data from seven European countries show a much better adherence to evidence and recommendations for oral anticoagulation.1 Interestingly, NOACs were given to younger patients and only to 6% of ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Rocio Hinojar, Jose Julio Jiménez-Natcher, Covadonga Fernández-Golfín, Jose Luis Zamorano

Date : 01/04/2015 Item size : 312462 bytes
Ehjcvp

[...]we have to recognize the pivotal role of the pharmaceutical industry in biomedical research since, given the lack of public funding, the majority of funded clinical trials in Europe and in the ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Giuseppe M.C. Rosano, Claudio Ceconi

Date : 01/04/2015 Item size : 102016 bytes
Ehjcvp

Furthermore, it is noteworthy that the lack of a carboxyl terminus renders CNP highly susceptible to cleavage by neprilysin (NEP).6 Physiologically CNP via activation of pGC-B exhibits antifibrotic ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Johann Wojta

Date : 01/04/2016 Item size : 144952 bytes
Ehjcvp

Given the burden of cardiovascular disease in patients with diabetes, the focus should shift towards cardiovascular outcome studies designed to evaluate efficacy (i.e. to determine the efficacy of a ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Faiez Zannad, Wendy Gattis Stough, Raymond J. Lipicky, Juan Tamargo, George L. Bakris, Jeffrey S. Borer, Maria de los Angeles Alonso ...

Date : 01/07/2016 Item size : 285307 bytes
Ehjcvp

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER The aim of this study was to use individual ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Björn W. Karlson, Olov Wiklund, Michael K. Palmer, Stephen J. Nicholls, Pia Lundman, Philip J. Barter

Date : 29/03/2016 Item size : 169375 bytes
Ehjcvp

Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Nucleus composition Chairperson Stefan Agewall, Norway Vice-chairperson Basil S. Lewis, Israel ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Basil S. Lewis, Stefan Agewall

Date : 01/01/2016 Item size : 109861 bytes
Ehjcvp

New oral anticoagulants are used in atrial fibrillation (AF) patients to prevent strokes in the primary and secondary prevention settings.1,2 Since AF are reported to be an independent risk factor ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Shinichi Goto, Shinya Goto

Date : 01/04/2015 Item size : 186244 bytes
Ehjcvp

Significant evidence demonstrated that atherosclerotic plaques are not passive collections of lipids, but sites of active interactions between cells of the immune system and vascular cells that ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Jessica Bullenkamp, Sip Dinkla, Juan Carlos Kaski, Ingrid E. Dumitriu

Date : 01/07/2016